Turin

• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS T … Recruiting
  2023-504084-17-00 9 2021-07-12 ALK fusion-positive extracranial solid or primary CNS tumors who have
• Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and the … Recruiting
  2022-501677-39-00 5 2021-05-25 Adolescent Renal Allografts
• An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l … Recruiting
  2024-511267-28-00 5 2021-02-17 B-cell malignancies
• A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zos … Recruiting
  2022-502784-37-00 4 2019-09-03 Prevention of Herpes Zoster in immunocompromised subjects aged 1-17 ye
• Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting
  2023-504694-20-00 9 2017-01-13 pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukem
• A Study to understand the Effectiveness, Safety, and what the body does to Mosunetuzumab in participants with Systemic Lupus Erythematosus w … Recruiting
  2024-519930-22-00 4 2026-05-18 Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephri
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E … Recruiting
  2025-523552-31-00 5 2026-05-07 Systemic Lupus Erythematosus
• A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Statur … Recruiting
  2025-523079-44-00 5 2026-04-15 Turner Syndrome (TS)
• Study to Assess the Ability of ONL1204 to Slow the Progression of Atrophic Age-related Macular Degeneration Recruiting
  2024-513174-22-00 4 2026-04-14 Atrophic Age-related Macular Degeneration (AMD)
• A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma Recruiting
  2025-524542-10-00 4 2026-04-14 Endometrial cancer
• Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Previously Untreated Advanced or Me … Recruiting
  2025-523263-37-00 10 2026-04-08 Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting
  2025-522674-36-00 5 2026-03-24 Metabolic Dysfunction-Associated Steatotic Liver Disease
• Zanubritnib and anti-MAG neuropathy Recruiting
  2025-523091-23-00 4 2026-03-24 Peripheral anti-MAG neuropathy, waldenstrom macroglobulinemia, margina
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-522713-29-00 5 2026-03-12 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• OCEAN(a)-CCTA - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction -Coronary Computed Tomography Angiography trial Recruiting
  2025-521117-88-00 5 2026-03-11 Cardiovascular Disease
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• Pembrolizumab plus Lenvatinib in vulvar cancer patients: The prospective, multi-cohorts and multicentre, phase 2 MITO VULVA-01 study. Recruiting
  2023-509180-24-00 4 2026-02-12 vulvar cancer
• A phase 2, randomized, double-blind study of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease. Recruiting
  2025-522146-40-00 4 2026-02-12 Late-onset Pompe disease.
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE … Recruiting
  2025-521802-17-00 5 2026-01-30 Erosive/inflammatory osteoarthritis of the hands
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Metastatic Clear Cell Renal Cell Carcinoma
• ​​Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy Recruiting
  2024-519404-27-00 5 2026-01-16 ​​IDH-mutant grade 2 or 3 astrocytoma​

Showing 121–144 of 632 trials